RECRUITINGINTERVENTIONAL

Fetal Cell Receptors Repertoire

"Study of CCR Receptor Overexpression in Fetal Microchimeric Cells: Proof of Concept Before a Potential Clinical Trial"

About This Trial

The purpose of this study is to describe the transcriptomic profile of foetal cells in post-partum and more specifically to determine which chemokine receptors are overexpressed in foetal cells in post-partum women with wounds To do so, the investigators will isolate foetal cells from the peripheral blood of healthy controls post partum women as well as from post partum women with skin ulcers and then perform RNA sequencing.

Who May Be Eligible (Plain English)

Who May Qualify: Common criteria : - Adult women, - Post-partum: having been pregnant for any length of time, - Having signed a free and willing to sign a consent form form, - Primiparous or multiparous, - Affiliated to a health insurance Patients : \- Patients with a venous, diabetic or sickle cell ulcer, or mixed ulcer Control group patients : - Volunteers, - Age-matched, - Without skin ulcers. There are no specific criteria for children. Who Should NOT Join This Trial: - Minors (for patients) - Under court protection, curatorship, guardianship (for patients) - Immunocompromised patients for any reason whatsoever - Refusal of consent - Refusal of blood and/or saliva samples for themselves or a member of their family Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: Common criteria : * Adult women, * Post-partum: having been pregnant for any length of time, * Having signed a free and informed consent form, * Primiparous or multiparous, * Affiliated to a health insurance Patients : \- Patients with a venous, diabetic or sickle cell ulcer, or mixed ulcer Control group patients : * Volunteers, * Age-matched, * Without skin ulcers. There are no specific criteria for children. Exclusion Criteria: * Minors (for patients) * Under court protection, curatorship, guardianship (for patients) * Immunocompromised patients for any reason whatsoever * Refusal of consent * Refusal of blood and/or saliva samples for themselves or a member of their family

Treatments Being Tested

OTHER

Saliva sampling

HLA genotyping. The technique should allow to identify, for children's, a paternal HLA antigen not shared with the mothers.

OTHER

Blood sampling

Maternal Blood samples will be incubated with the appropriate antibody, targeting the microchimeric fetal cells of each patient, as well as with a cell viability marker (DAPI). The samples were then be processed through the BD FACS Aria III to sort the fetal cells, The following steps - RNA extraction, quality control, retrotranscription, preparation of the library, sequencing and transcriptomic analysis - will be carried out according to the Smart-seq3 protocol. The data will be sent for in-depth analysis and confirmation of the results. Additional functional experiments may also be carried out.

OTHER

Interviews

V2 and/or V3

OTHER

Clinical examination

V2 and/or V3

Locations (1)

Dermatology unit - Cochin Hospital - APHP

Paris, Île-de-France Region, France